ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

New Glucose reabsorption inhibitors (SGLT2) dapagliflozin and sergliflozin are pending FDA approval

Updated on December 21, 2011

New class of antidiabetic drugs?

SGLT2 inhibitors inhibit glucose reabsorption from the kidneys. Therefore, these drugs reduce blood glucose levels even in extreme insulin deficiency. This new drug class was developed by the pharmaceutical company Bristol-Myers Squibb in partnership with AstraZeneca and GlaxoSmithkline. AstraZeneca developed dapagliflozine and GlaxoSmithline developed sergliflozin.

But these drugs are still in the phase three trails. That means they are still being tested for effectiveness in the watchful eye of the FDA.

But taking these drugs immediately after they are released to the market is not recommended. it is because they can cause various unidentified side effects. In addition, this drug is tested in combination of other anti diabetic drugs and it seems it is not effective alone. Therefore, the patients need to take these drugs with other conventional anti diabetic drugs.

Conclusion

Dapagliflozin and sergliflozin are new class of ant - diabetic drugs developed by pharmaceutical compnaies Astrazeneca, Bristol-Myers Squibb, and GlaxoSmithline. They inhibit glucose re-absorption from the kidneys and decrease the blood glucose levels. However, it is too early for the patients to try this new treatment option.

Are you going to take these new drugs, once they are available

See results

Guestbook Comments

    0 of 8192 characters used
    Post Comment

    • akumar46 lm profile image

      akumar46 lm 6 years ago

      Nice information on new drugs for diabetes.